Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma has presented efficacy, safety and biodistribution results on its new biotherapy AMEP for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, DC (May 17- 22, 2010).
Subscribe to our email newsletter
The AMEP biotherapy’s original mechanism of action targets specific receptors (integrins) involved in tumor growth and in tumor angiogenesis.
Efficacy studies demonstrated that AMEPTM administration in human melanoma xenograft models induced a higher tumor growth inhibition than with Temozolomide, the standard chemotherapy used in metastatic melanoma treatment.
Safety and biodistribution studies showed a good overall tolerance with AMEP and a progressive elimination from tissues without accumulation.
Based on the results, AMEP phase I clinical trial has been initiated for the treatment of advanced and metastatic melanoma in France, Denmark and Slovenia.
BioAlliance has been granted EUR6.4m from OSEO (the French state innovation agency) which finances technological breakthrough projects.